The news flow around Novo Nordisk has rarely been more divided. On one side, a confirmed cyber attack that exposed pseudonymised patient data from clinical trials. On the other, a regulatory green light for oral Wegovy in the UK, more than three million US prescriptions for the same pill, and a looming FDA decision on the next-generation weight-loss drug CagriSema. The market has cast its vote: shares climbed 2.4% to around €38.06, signaling that traders see the operational setbacks as manageable and the product momentum as genuine.
The oral formulation of semaglutide is fast becoming the Danish drugmaker’s most tangible near-term growth engine. Britain’s MHRA approved the once-daily tablet for weight management this week, making the UK the third major market after the US and the United Arab Emirates. The decision rests on the OASIS-4 trial, where participants lost 16.6% of their body weight over 64 weeks compared with placebo. In the US, where the pill launched roughly five months ago, more than three million prescriptions have already been written. Crucially, over 80% of those patients had never taken a GLP-1 drug before — a clear market-expansion effect rather than simple cannibalisation of the injectable Wegovy.
That expansion is about to get a further boost from Washington. From 1 July 2026, the Medicare GLP-1 Bridge Program will give eligible Part D beneficiaries access to Wegovy for a monthly copay of $50. CEO Mike Doustdar sees this as a chance to claw back ground lost to Eli Lilly’s Zepbound, noting that Wegovy remains the only weight-loss drug proven to cut heart attacks, strokes and cardiovascular death in patients with existing heart disease. In an older Medicare population with a high burden of cardiovascular disease, that differentiating factor could prove decisive.
Yet the competitive landscape remains daunting. At the American Diabetes Association congress in New Orleans, Novo presented Phase 3 data from the REIMAGINE 1–3 studies showing CagriSema delivered weight reductions of slightly over 14% in type 2 diabetics, along with meaningful HbA1c improvements. In a separate obesity study, the combination of a GLP-1 receptor agonist and an amylin analogue produced 23% weight loss after 84 weeks. Both are solid numbers. The problem is that Lilly showed results for its experimental triple-agonist Retatrutide that reached more than 30% weight loss over two years in certain obesity patients. The gap is hard to ignore, and Novo’s own chief scientific officer conceded it is too early to judge which molecule will ultimately prevail — a scientifically honest statement that does little to reassure investors.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Novo has already submitted CagriSema for FDA approval in weight management, with a decision expected in the fourth quarter of 2026. A green light would give the company a credible next-generation product for 2027, one that sits comfortably above Wegovy’s current efficacy but still trails Retatrutide’s peak. In the longer run, the pipeline also includes Zenagamtide and oral semaglutide in other indications, providing depth beyond CagriSema alone.
Amid these strategic moves, the cyber incident announced on 11 June has been a sideshow rather than a central drama. Unauthorised third parties accessed internal systems and copied non-public data, including pseudonymised patient information from clinical trials such as IDs, birth years and health records. Novo took systems offline and brought in external experts, but stressed that core operations, production and the pipeline remain unaffected. The stock’s positive reaction suggests the market views this as an operational nuisance rather than a business-model threat.
The technical picture reflects a stock in limbo. At €38.06, it trades 46% below last year’s high of €70.13 and remains 8% under its 200-day moving average of €41.47, although it has crept 5% above the 50-day average of €36.25. The relative strength index at 53.8 points to neutral territory — no longer a zone of panic, but far from a recovery. Novo recently narrowed its full-year guidance, now pencilling in a constant-currency decline in revenue and operating profit of 4% to 12%, versus a prior range of 5% to 13%. That nudge upward signals that the worst-case scenario is becoming less likely, yet it is no endorsement of a quick rebound.
For investors, the next six months offer a trio of catalysts: the ramp in US pill prescriptions and the Medicare tailwind in July, the UK rollout over the summer with broader market access due in the second half of 2026, and the all-important FDA verdict on CagriSema before year-end. Each could prompt a reassessment of a stock that carries an annualised volatility of nearly 33% and a valuation that already assumes a prolonged catch-up phase rather than a return to market leadership. The cyber attack may generate regulatory questions, but it does not alter the fundamental equation — Novo Nordisk has both the product breadth and the pipeline ambiguity to keep the debate alive.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from June 12 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 12.
Novo Nordisk: Buy or sell? Read more here...
